A Phase 1, Open-label, Non-Randomized, Dose Escalation Trial to Evaluate Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs OPB 111077 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- Sponsors Korea Otsuka Pharmaceutical
- 09 Sep 2019 Status changed from active, no longer recruiting to completed.
- 04 Jan 2019 Planned End Date changed from 1 Dec 2018 to 1 Aug 2019.
- 04 Jan 2019 Planned primary completion date changed from 1 May 2018 to 1 Feb 2019.